Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
199 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides an overview of the Waldenstrom Macroglobulinemia (Oncology) pipeline landscape. Waldenstrom macroglobulinemia (WM) is a type of non-Hodgkin lymphoma (NHL) that produces large amounts of an abnormal protein (called a macroglobulin). Risk factors include age, gender, family history, Hepatitis C and certain types of autoimmune disease, such as Sjogren syndrome, might be at higher risk for WM. Treatment includes stem cell transplantation, biological therapy, chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Waldenstrom Macroglobulinemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 16, 10, 1 and 3 respectively for Waldenstrom Macroglobulinemia. Waldenstrom Macroglobulinemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia (Oncology). - The pipeline guide reviews pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Waldenstrom Macroglobulinemia (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Waldenstrom Macroglobulinemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Waldenstrom Macroglobulinemia (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Waldenstrom Macroglobulinemia Overview 9 Therapeutics Development 10 Pipeline Products for Waldenstrom Macroglobulinemia - Overview 10 Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies 11 Waldenstrom Macroglobulinemia - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Waldenstrom Macroglobulinemia - Products under Development by Companies 16 Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development 18 AbbVie Inc 18 Amgen Inc. 19 arGEN-X BV 20 Aurigene Discovery Technologies Limited 21 Bayer AG 22 BeiGene, Ltd. 23 Calithera Biosciences, Inc. 24 Celgene Corporation 25 Genentech, Inc. 26 Gilead Sciences, Inc. 27 Hutchison MediPharma Limited 28 IGF Oncology, LLC. 29 Incyte Corporation 30 Juno Therapeutics Inc. 31 Karyopharm Therapeutics, Inc. 32 Merck KGaA 33 Millennium Pharmaceuticals Inc 34 Novartis AG 35 Ono Pharmaceutical Co., Ltd. 36 Portola Pharmaceuticals, Inc. 37 Takeda Pharmaceutical Company Limited 38 Vivolux AB 39 Waldenstrom Macroglobulinemia - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Combination Products 41 Assessment by Target 42 Assessment by Mechanism of Action 45 Assessment by Route of Administration 47 Assessment by Molecule Type 49 Drug Profiles 51 (dezapelisib + itacitinib adipate) - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 765IGF-MTX - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 acalabrutinib - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 alisertib - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 ARGX-110 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 BGB-3111 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 bortezomib - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 CA-4948 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 carfilzomib - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 CB-839 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 cerdulatinib - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 copanlisib hydrochloride - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 dezapelisib - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 DI-B4 - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 DTRMWXHS-12 - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 entospletinib - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 everolimus - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 HMPL-523 - Drug Profile 122 Product Description 122 Mechanism Of Action 122 R&D Progress 122 INCB-50465 - Drug Profile 124 Product Description 124 Mechanism Of Action 124 R&D Progress 124 itacitinib adipate - Drug Profile 125 Product Description 125 Mechanism Of Action 125 R&D Progress 125 ixazomib citrate - Drug Profile 128 Product Description 128 Mechanism Of Action 128 R&D Progress 128 JCAR-015 - Drug Profile 137 Product Description 137 Mechanism Of Action 137 R&D Progress 137 lenalidomide - Drug Profile 142 Product Description 142 Mechanism Of Action 142 R&D Progress 142 M-7583 - Drug Profile 156 Product Description 156 Mechanism Of Action 156 R&D Progress 156 ONO-4059 - Drug Profile 157 Product Description 157 Mechanism Of Action 157 R&D Progress 157 oprozomib - Drug Profile 159 Product Description 159 Mechanism Of Action 159 R&D Progress 159 selinexor - Drug Profile 162 Product Description 162 Mechanism Of Action 162 R&D Progress 162 Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile 180 Product Description 180 Mechanism Of Action 180 R&D Progress 180 spebrutinib besylate - Drug Profile 181 Product Description 181 Mechanism Of Action 181 R&D Progress 181 TAK-659 - Drug Profile 183 Product Description 183 Mechanism Of Action 183 R&D Progress 183 venetoclax - Drug Profile 184 Product Description 184 Mechanism Of Action 184 R&D Progress 184 VLX-1570 - Drug Profile 194 Product Description 194 Mechanism Of Action 194 R&D Progress 194 Waldenstrom Macroglobulinemia - Dormant Projects 196 Waldenstrom Macroglobulinemia - Discontinued Products 197 Appendix 198 Methodology 198 Coverage 198 Secondary Research 198 Primary Research 198 Expert Panel Validation 198 Contact Us 198 Disclaimer 199
List of Tables
Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016 10 Number of Products under Development by Companies, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 (Contd..1) 17 Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc, H2 2016 18 Waldenstrom Macroglobulinemia - Pipeline by Amgen Inc., H2 2016 19 Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H2 2016 20 Waldenstrom Macroglobulinemia - Pipeline by Aurigene Discovery Technologies Limited, H2 2016 21 Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H2 2016 22 Waldenstrom Macroglobulinemia - Pipeline by BeiGene, Ltd., H2 2016 23 Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H2 2016 24 Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H2 2016 25 Waldenstrom Macroglobulinemia - Pipeline by Genentech, Inc., H2 2016 26 Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H2 2016 27 Waldenstrom Macroglobulinemia - Pipeline by Hutchison MediPharma Limited, H2 2016 28 Waldenstrom Macroglobulinemia - Pipeline by IGF Oncology, LLC., H2 2016 29 Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H2 2016 30 Waldenstrom Macroglobulinemia - Pipeline by Juno Therapeutics Inc., H2 2016 31 Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 32 Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H2 2016 33 Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 34 Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H2 2016 35 Waldenstrom Macroglobulinemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 36 Waldenstrom Macroglobulinemia - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 37 Waldenstrom Macroglobulinemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 38 Waldenstrom Macroglobulinemia - Pipeline by Vivolux AB, H2 2016 39 Assessment by Monotherapy Products, H2 2016 40 Assessment by Combination Products, H2 2016 41 Number of Products by Stage and Target, H2 2016 43 Number of Products by Stage and Mechanism of Action, H2 2016 46 Number of Products by Stage and Route of Administration, H2 2016 48 Number of Products by Stage and Molecule Type, H2 2016 50 Waldenstrom Macroglobulinemia - Dormant Projects, H2 2016 196 Waldenstrom Macroglobulinemia - Discontinued Products, H2 2016 197
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
